Stay tuned for our LIVE OncLive News Network coverage straight from the #ASH18 conference floor! 

Dr. Conroy Discusses Survival Data With FOLFIRINOX in Pancreatic Cancer

Thierry Conroy, MD
Published: Wednesday, Jun 20, 2018



Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses survival data with modified FOLFIRINOX (mFOLFIRINOX) in pancreatic cancer.

Investigators suggest that recent phase III findings of mFOLFIRINOX in patients with resected pancreatic cancer have solidified a new adjuvant standard of care for patients who are fit enough to undergo the chemotherapy combination after surgery.

Conroy says that disease-free survival (DFS) was the main objective of the trial, and there was a very important increase in favor of patients treated with mFOLFIRINOX. The median DFS for patients treated with mFOLFIRINOX was 21.6 months compared with 12.8 months with gemcitabine (HR, 0.58; 95% CI, 0.46-0.73; P <.001) at a follow-up of 33.6 months. At 3 years, the DFS was 39.7% with mFOLFIRINOX and 21.4% with gemcitabine.

There was also an over 40% reduction in the rate of metastases with mFOLFIRINOX, Conroy says. The median overall survival was almost 20 months longer than with gemcitabine at 54.4 versus 35.0 months. This represents at 36% reduction in the risk of death (HR, 0.64; 95% CI, 0.48-0.86; P = .003).


Thierry Conroy, MD, medical oncologist, director, Institut de Cancerologie de Lorraine, discusses survival data with modified FOLFIRINOX (mFOLFIRINOX) in pancreatic cancer.

Investigators suggest that recent phase III findings of mFOLFIRINOX in patients with resected pancreatic cancer have solidified a new adjuvant standard of care for patients who are fit enough to undergo the chemotherapy combination after surgery.

Conroy says that disease-free survival (DFS) was the main objective of the trial, and there was a very important increase in favor of patients treated with mFOLFIRINOX. The median DFS for patients treated with mFOLFIRINOX was 21.6 months compared with 12.8 months with gemcitabine (HR, 0.58; 95% CI, 0.46-0.73; P <.001) at a follow-up of 33.6 months. At 3 years, the DFS was 39.7% with mFOLFIRINOX and 21.4% with gemcitabine.

There was also an over 40% reduction in the rate of metastases with mFOLFIRINOX, Conroy says. The median overall survival was almost 20 months longer than with gemcitabine at 54.4 versus 35.0 months. This represents at 36% reduction in the risk of death (HR, 0.64; 95% CI, 0.48-0.86; P = .003).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Oncology Briefings™: Individualizing Treatment After Second-Line Therapy for Patients With mCRCAug 29, 20191.0
Community Practice Connections™: Navigating New Sequencing Challenges for the Treatment of Hepatocellular CarcinomaAug 30, 20191.5
Publication Bottom Border
Border Publication
x